Skip to main content

Table 1 Demographic, clinical and laboratory characteristics for patients at baseline and at the 3-month visit (time for randomisation)

From: Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

  Treatment A (n= 22) Treatment B (n= 18)
Baseline   
   Age (years) 59.5 (58.0 to 67.0) 56.0 (42.0 to 73.0)
   Women 16 (73%) 13 (72%)
   Menopause 14 (88%) 8 (62%)
   Current or previous smoker 15(68%) 7 (41%)
   Disease duration (months) 5.4 (2.9) 4.9 (3.4)
   Rheumatoid factor positivity 11 (50%) 10 (56%)
   X-ray criteria at baseline 7 (32%) 2 (11%)
3-month visit   
   Erythrocyte sedimentation rate (mm) 25.0 (14.0 to 29.0) 23.5 (12.0 to 34.0)
   Disease Activity Score of 28 joints 4.3 (4.1 to 4.9) 4.8 (3.7 to 5.1)
   HAQ score 0.86 (0.50) 0.89 (0.18)
   Leptin (μg/l) 8.8 (5.4 to 27.7) 7.9 (3.9 to 14.2)
   Adiponectin (mg/l) 10.7 (3.4) 10.9 (6.6)
   Apolipoprotein A1 (g/l) 1.46 (0.25) 1.64 (0.23)
   Apolipoprotein B (g/l) 1.10 (0.26) 1.03 (0.21)
   Apolipoprotein B/apolipoprotein A1 0.77 (0.24) 0.64 (0.15)
   P1NP (μg/l) 46 (36 to 58) 43 (32 to 68)
   CTX-1 (pg/ml) 280 (191 to 368) 233 (119 to 457)
   1CTP (μg/l) 4.1 (3.3 to 5.6) 3.7 (2.9 to 4.9)
   IGF-1 (μg/l) 145.5 (114.0 to 166.0) 154.5 (130.0 to 193.0)
   IGF-1 SD scores -0.09 (1.34) -0.07 (-0.12)
  1. Demographic, clinical and laboratory characteristics at baseline and at the 3-month visit (time for randomisation). Data presented as median (interquartile range), n (%) or mean (standard deviation (SD)). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate + infliximab. HAQ, Health Assessment Questionnaire, P1NP, procollagen type I N-terminal propeptide; CTX-1, C-terminal telopeptide of type I collagen; 1CTP, C-terminal propeptide of type I collagen; IGF-1, insulin-like growth factor-1.